Literature DB >> 21422222

Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.

Mathilde Richard1, Olivier Ferraris, Alexandra Erny, Mendy Barthélémy, Aurélien Traversier, Murielle Sabatier, Alan Hay, Yi Pu Lin, Rupert J Russell, Bruno Lina.   

Abstract

Neuraminidase (NA) inhibitors (NIs) are the first line of defense against influenza virus. Reverse genetics experiments allow the study of resistance mechanisms by anticipating the impacts of mutations to the virus. To look at the possibility of an increased effect on the resistance phenotype of a combination of framework mutations, known to confer resistance to oseltamivir or zanamivir, with limited effect on virus fitness, we constructed 4 viruses by reverse genetics in the A/Moscow/10/99 H3N2 background containing double mutations in their neuraminidase genes: E119D+I222L, E119V+I222L, D198N+I222L, and H274Y+I222L (N2 numbering). Among the viruses produced, the E119D+I222L mutant virus was not able to grow without bacterial NA complementation and the D198N+I222L mutant and H274Y+I222L mutant were not stable after passages in MDCK cells. The E119V+I222L mutant was stable after five passages in MDCK cells. This E119V-and-I222L combination had a combinatorial effect on oseltamivir resistance. The total NA activity of the E119V+I222L mutant was low (5% compared to that of the wild-type virus). This drop in NA activity resulted from a decreased NA quantity in the virion in comparison to that of the wild-type virus (1.4% of that of the wild type). In MDCK-SIAT1 cells, the E119V+I222L mutant virus did not present a replicative advantage over the wild-type virus, even in the presence of oseltamivir. Double mutations combining two framework mutations in the NA gene still have to be monitored, as they could induce a high level of resistance to NIs, without impairing the NA affinity. Our study allows a better understanding of the diversity of the mechanisms of resistance to NIs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422222      PMCID: PMC3101467          DOI: 10.1128/AAC.01699-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  65 in total

1.  Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.

Authors:  Hui-Ling Yen; Louise M Herlocher; Erich Hoffmann; Mikhail N Matrosovich; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  A DNA transfection system for generation of influenza A virus from eight plasmids.

Authors:  E Hoffmann; G Neumann; Y Kawaoka; G Hobom; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.

Authors:  Vasiliy P Mishin; Frederick G Hayden; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.

Authors:  Margaret Okomo-Adhiambo; Gail J Demmler-Harrison; Varough M Deyde; Tiffany G Sheu; Xiyan Xu; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

5.  Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study.

Authors:  N K Sauter; M D Bednarski; B A Wurzburg; J E Hanson; G M Whitesides; J J Skehel; D C Wiley
Journal:  Biochemistry       Date:  1989-10-17       Impact factor: 3.162

6.  Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution.

Authors:  J N Varghese; P M Colman
Journal:  J Mol Biol       Date:  1991-09-20       Impact factor: 5.469

7.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.

Authors:  M Louise Herlocher; Rachel Truscon; Stephanie Elias; Hui-Ling Yen; Noel A Roberts; Suzanne E Ohmit; Arnold S Monto
Journal:  J Infect Dis       Date:  2004-09-28       Impact factor: 5.226

8.  Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.

Authors:  Aeron C Hurt; Ian G Barr; Gunter Hartel; Alan W Hampson
Journal:  Antiviral Res       Date:  2004-04       Impact factor: 5.970

9.  Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.

Authors:  Mariana Baz; Yacine Abed; Philippe Simon; Marie-Eve Hamelin; Guy Boivin
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

10.  Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.

Authors:  Santosh Rudrawar; Jeffrey C Dyason; Marie-Anne Rameix-Welti; Faith J Rose; Philip S Kerry; Rupert J M Russell; Sylvie van der Werf; Robin J Thomson; Nadia Naffakh; Mark von Itzstein
Journal:  Nat Commun       Date:  2010-11-16       Impact factor: 14.919

View more
  16 in total

1.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

2.  An Amino Acid in the Stalk Domain of N1 Neuraminidase Is Critical for Enzymatic Activity.

Authors:  Mark Zanin; Susu Duan; Sook-San Wong; Gyanendra Kumar; Pradyumna Baviskar; Emily Collin; Charles Russell; Subrata Barman; Benjamin Hause; Richard Webby
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

3.  Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

Authors:  Henju Marjuki; Vasiliy P Mishin; Anton P Chesnokov; Joyce Jones; Juan A De La Cruz; Katrina Sleeman; Daisuke Tamura; Ha T Nguyen; Ho-Sheng Wu; Feng-Yee Chang; Ming-Tsan Liu; Alicia M Fry; Nancy J Cox; Julie M Villanueva; Charles T Davis; Larisa V Gubareva
Journal:  J Infect Dis       Date:  2014-08-14       Impact factor: 5.226

4.  Structural and inhibitor sensitivity analysis of influenza B-like viral neuraminidases derived from Asiatic toad and spiny eel.

Authors:  Linghui Li; Yan Chai; Weiyu Peng; Delin Li; Litao Sun; George Fu Gao; Jianxun Qi; Haixia Xiao; William Jun Liu; Mark von Itzstein; Feng Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-03       Impact factor: 12.779

5.  A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.

Authors:  Lan Huang; Yang Cao; Jianfang Zhou; Kun Qin; Wenfei Zhu; Yun Zhu; Lei Yang; Dayan Wang; Hong Wei; Yuelong Shu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

6.  Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.

Authors:  Yan Wu; Feng Gao; Jianxun Qi; Yuhai Bi; Lifeng Fu; Sankar Mohan; Yuhang Chen; Xuebing Li; B Mario Pinto; Christopher J Vavricka; Po Tien; George F Gao
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

7.  Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.

Authors:  Camilly P Pires de Mello; George L Drusano; Jonathan R Adams; Matthew Shudt; Robert Kulawy; Ashley N Brown
Journal:  Eur J Pharm Sci       Date:  2017-10-25       Impact factor: 4.384

Review 8.  New treatments for influenza.

Authors:  Sailen Barik
Journal:  BMC Med       Date:  2012-09-13       Impact factor: 8.775

9.  Simultaneous detection of oseltamivir- and amantadine-resistant influenza by oligonucleotide microarray visualization.

Authors:  Yingjie Zhang; Qiqi Liu; Dou Wang; Suhong Chen; Shengqi Wang
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

10.  Rescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinity.

Authors:  Mathilde Richard; Alexandra Erny; Bertrand Caré; Aurélien Traversier; Mendy Barthélémy; Alan Hay; Yi Pu Lin; Olivier Ferraris; Bruno Lina
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.